Show simple item record

dc.contributor.authorShapiro, Nancy L.
dc.contributor.authorKominiarek, Michelle A.
dc.contributor.authorNutescu, Edith A.
dc.contributor.authorChevalier, Aimee B.
dc.contributor.authorHibbard, Judith U.
dc.date.accessioned2012-08-17T04:29:03Z
dc.date.available2012-08-17T04:29:03Z
dc.date.issued2011-07
dc.identifier.bibliographicCitationShapiro, N. L., Kominiarek, M. A., Nutescu, E. A., Chevalier, A. B., & Hibbard, J. U. 2011. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: Single-center experience. Pharmacotherapy, 31(7): 678-685. DOI: 10.1592/phco.31.7.678.en
dc.identifier.issn0277-0008
dc.identifier.otherDOI: 10.1592/phco.31.7.678
dc.identifier.urihttp://hdl.handle.net/10027/8520
dc.description© 2011 by IOS Press, Pharmacotherapy Post print version of article may differ from published version. The definitive version is available through IOS Press at DOI: 10.1592/phco.31.7.678.en
dc.description.abstractStudy Objective. To evaluate dosing requirements and monitoring patterns of low-molecular-weight heparin (LMWH) when used in high-risk pregnancy. Design. Retrospective, observational, cohort study. Setting. University-affiliated medical center. Patients. Forty-nine women treated with LMWH between 2001 and 2005 for either prophylaxis or treatment of venous thromboembolism during pregnancy and monitored with antifactor Xa activity. Measurements and Main Results. Data were obtained on 53 pregnancies in the 49 women. The primary outcome was change in dosing requirements of LMWH throughout pregnancy as determined by the corresponding antifactor Xa activity peak levels. Mean starting doses of twice-daily enoxaparin and doses most proximate to delivery were 39.2 mg (range 30– 60 mg) and 55.0 mg (range 30–100 mg, p=0.06), respectively, for the prophylaxis group and 83.0 mg (range 30–180 mg) and 85.7 mg (range 30–160 mg, p=0.41), respectively, for the therapeutic group. Weight-based mean starting doses and doses most proximate to delivery were 0.46 and 0.62 mg/kg (p=0.03), respectively, for the prophylaxis group and 0.90 and 0.87 mg/kg (p=0.29), respectively, for the therapeutic group. Dose changes were required in 9 (69%) of 13 pregnancies and 21 (55%) of 38 pregnancies (data from two of the 40 pregnancies were excluded—one in a patient receiving dalteparin, and one in a patient with mitral valve replacement who had higher antifactor Xa goals) in the prophylaxis and therapeutic groups, respectively, to achieve target antifactor Xa activity. The weight-based prophylactic dose was consistently 0.6 mg/kg in all three trimesters, achieving a mean ± SD target antifactor Xa activity of 0.39 ± 0.18 units/ml, whereas the therapeutic dose was 0.9 mg/kg to maintain antifactor Xa activity of 0.71 ± 0.22 units/ml. Conclusion. Dose changes for LMWH throughout pregnancy as guided by antifactor Xa activity were common. A significant increase in the LMWH dose requirements in the prophylactic group suggests that more frequent monitoring of antifactor Xa activity may be appropriate in pregnant patients to maintain target anticoagulant levels.en
dc.language.isoen_USen
dc.publisherIOS Pressen
dc.subjectpregnancyen
dc.subjectLow-Molecular-Weight Heparinen
dc.titleDosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: Single-center experienceen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record